Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Stealth BioTherapeutics Corp (MITO)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.3120+0.0009 (+0.29%)
At close: 03:56PM EDT
0.3110 -0.00 (-0.32%)
After hours: 04:42PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.3111
Open0.3107
Bid0.3110 x 1000
Ask0.3131 x 1300
Day's Range0.3107 - 0.3134
52 Week Range0.1620 - 1.5000
Volume65,739
Avg. Volume384,103
Market Cap22.918M
Beta (5Y Monthly)1.63
PE Ratio (TTM)N/A
EPS (TTM)-0.9240
Earnings DateNov 11, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est1.77
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for MITO

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Stealth BioTherapeutics Corp.
    Analyst Report: Ionis Pharmaceuticals, Inc.Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and partner Biogen brought Spinraza to market in 2016 as a treatment for a rare neuromuscular disorder, spinal muscular atrophy. Ionis subsequently brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019).
    Rating
    Fair Value
    Economic Moat
    21 days agoMorningstar
View more
  • PR Newswire

    Stealth BioTherapeutics Announces Departure of Chief Financial Officer

    Stealth BioTherapeutics Corp (Nasdaq:MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that Robert Weiskopf, Stealth's chief financial officer, is leaving the company effective September 30, 2022. Mr. Weiskopf joined Stealth in 2019 following the company's initial public offering to spearhead its public financial reporting activities and grow the Company's

  • PR Newswire

    Stealth BioTherapeutics to Participate in Upcoming Ultra-Rare Disease Events

    Stealth BioTherapeutics Corp (NASDAQ: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company is participating in upcoming events to discuss challenges and opportunities in ultra-rare disease drug development.

  • Benzinga

    Stealth BioTherapeutics Enters Going Private Agreement

    Stealth BioTherapeutics Corp (NASDAQ: MITO) will be acquired by a consortium of investors led by Morningside Venture (I) Investments Ltd and J. Wood Capital Advisors LLC in an all-cash transaction. Each Stealth Bio will be canceled and cease to exist for the right to receive $0.03125 in cash. Each American Depositary Share representing 12 shares will be canceled for the right to receive $0.375. Related: Stealth Bio Shares Trading Higher On Pre-Clinical Presentation Of Neuromuscular Disease Candi

Advertisement
Advertisement